

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

**(1) QUARTERLY UPDATE ON STATUS OF RESUMPTION; AND
(2) RESUMPTION OF TRADING**

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 1 April 2025 in relation to, among other things, the delay in publication of the 2024 annual results, and possible suspension of trading; (ii) the announcement of the Company dated 25 April 2025 in relation to the change of auditors; (iii) the supplemental announcement of the Company dated 30 May 2025 in relation to the subscription of funds and temporary deviation from the use of IPO proceeds; and (iv) the announcement of the Company dated 30 June 2025 in relation to the annual results announcement for the year ended 31 December 2024 (collectively, the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless the context requires otherwise.

Pursuant to Rule 13.24A of the Listing Rules, the Board wishes to inform the Company’s shareholders and potential investors on the progress of actions taken by the Company to address the resumption requirement under the Listing Rules with a view to seeking resumption of trading in the shares of the Company as soon as practicable.

QUARTERLY UPDATE ON STATUS OF RESUMPTION

Business Operations

The Group is principally engaged in the research and development (“R&D”), manufacturing and sale of innovative drugs. The Group continues to operate its business in the ordinary and usual course as at the date of this announcement.

Update on Resumption Progress

The Company is taking appropriate steps to fulfill the resumption requirement under the Listing Rules. The status of resumption since the suspension of trading in the shares of the Company are summarised as follows:

Financial results

As disclosed in the Announcements, the publication of the 2024 annual results have been delayed. As at the date of this announcement, the 2024 annual audit has been completed, and the 2024 annual results has been published on 30 June 2025.

Temporary deviation from the use of IPO proceeds

As disclosed in the Announcements, the deviation from the use of the IPO Proceeds was an inadvertent oversight. As at the date of this announcement, the IPO Proceeds allocated for the subscription of the Investments have been fully recovered and will not have any impact on the subsequent normal use of the IPO Proceeds in accordance with the stated purposes as disclosed in the Prospectus or the normal operations of the Company. To prevent similar situations in the future, the Company has reviewed its internal procedures and taken several remedial measures. For details, please refer to the Company’s announcement dated 25 February 2025 and 30 May 2025.

RESUMPTION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules and at the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025. In light of the publication of the annual results announcement for the year ended 31 December 2024 on 30 June 2025, an application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares with effect from 9:00 a.m. on 2 July 2025.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 30 June 2025

As at the date of this notice, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.